Matteo Landriscina

34PUBLICATIONS
114CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisMolecular targetsLiquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Sep 26, 2026
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy.

|Dec 30, 2025
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Palma Fedele, Alessandro Rizzo, Matteo Landriscina

|Dec 24, 2025
The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.

Alberto Bongiovanni, Pierfranco Conte, Vincenza Conteduca

|Nov 13, 2025
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Palma Fedele, Stefania Luigia Stucci, Matteo Landriscina

|Nov 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.

Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda

|Oct 29, 2025
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2- Metastatic Breast Cancer: A Real-World Multicenter Study.

Palma Fedele, Matteo Landriscina, Lucia Moraca

Pageof 6

Frequent Collaborators

8 joint publications

Franca Esposito

7 joint publications

Fabiana Crispo

7 joint publications

Magda Zanelli

7 joint publications

Andrea Palicelli